Highlights
- ALS (ASX:ALQ) reported FY26 underlying net profit of AUD 381.2 million, up 25.8% from FY25.
- Commodities Revenue increased 18.8% as Minerals testing volumes and pricing contributed to growth.
- The company opened a geochemistry hub laboratory in Lima, Peru, in October 2026.
- Its H1 FY27 results are scheduled for 23 November, following previously issued organic growth guidance.
ALS (ASX:ALQ) provides laboratory testing, inspection and analytical services to customers in mining, environmental, food and pharmaceutical markets. Its FY26 results reflected increased Demand for minerals analysis alongside more varied conditions across Life Sciences. With a new geochemistry laboratory opened in Peru and half-year results approaching, attention now turns to how those developments are reflected in FY27 operations.
FY26 Earnings Reflect Higher Testing Activity and Improved Margins
For the year ended 31 March 2026, ALS reported revenue of AUD 3,320.1 million, compared with AUD 2,999.4 million in FY25. Underlying earnings before interest and tax increased 19.3% to AUD 599.0 million, while the group underlying EBIT Margin reached 18.0%, an improvement of approximately 129 basis points. Underlying net profit rose 25.8% to AUD 381.2 million.
Statutory net profit after tax was AUD 318.7 million, compared with AUD 256.2 million a year earlier. Underlying earnings exclude specified restructuring and other items. Cash Flow before Capital Expenditure increased to AUD 674.1 million from AUD 590.6 million. Net Debt fell to AUD 1,069.5 million from AUD 1,424.1 million. Total FY26 dividends were 42.5 Australian cents per share, against 38.6 cents in FY25.
Minerals Growth Contrasts With Mixed Life Sciences Trends
The Commodities division supplied much of the earnings momentum. Revenue advanced 18.8% to AUD 1,294.2 million, and underlying EBIT increased 25.9% to AUD 381.5 million. Minerals organic revenue rose 20.2% on higher sample volumes and improving pricing. Minerals EBIT margin reached 33.0%.
Life Sciences reported a more uneven result. Its revenue rose 6.0% to AUD 2,025.9 million and underlying EBIT increased 10.2% to AUD 296.5 million. Food delivered 7.2% organic revenue growth, while pharmaceutical organic revenue declined 1.6% and environmental trading conditions differed across markets. ALS also reported completion of its Nuvisan transformation programme, with an approximately EUR 25 million annualised cost-reduction exit run rate.
Lima Laboratory Opening Advances the Network Investment Programme
Beyond its FY26 earnings, ALS has been investing in laboratory infrastructure to expand analytical capacity. Its broader hub programme includes facilities in Lima, Sydney, Bangkok and Prague, with an indicated total investment of approximately AUD 230 million.
An October 2026 company announcement confirmed the opening of the new Lima geochemistry hub. ALS stated that the Facility represented an investment of approximately AUD 70 million and had capacity to process more than four million samples annually. Future returns will depend on utilisation and demand.
FY27 Guidance and the November Reporting Milestone
ALS previously guided to mid-to-high single-digit group organic revenue growth for FY27 and 13%–15% organic growth in Minerals, including a 15%–17% first-half range. Management also identified a potential AUD 5 million–10 million earnings exposure associated with conditions in the Middle East. These are forecasts, not reported results.
The company has scheduled its H1 FY27 results for 23 November 2026. It should clarify Minerals margins, Life Sciences trading and capacity utilisation. The half-year outcome is not yet known.
Key Insights
ALS entered FY27 after higher FY26 earnings, a larger contribution from Minerals and reduced net debt. The Lima opening adds testing capacity. Mixed Life Sciences conditions and Middle East exposure remain relevant uncertainties ahead of the scheduled half-year update.


_11_19_2026_05_50_58_177297.jpg)



Please wait processing your request...